Genkyotex S.A., a biopharmaceutical company, develops oral small molecule NOX therapeutics.
Mediocre balance sheet and overvalued.
Share Price & News
How has Genkyotex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: G061 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: G061 underperformed the German Biotechs industry which returned 7.2% over the past year.
Return vs Market: G061 underperformed the German Market which returned 14.1% over the past year.
Price Volatility Vs. Market
How volatile is Genkyotex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Genkyotex undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate G061's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate G061's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: G061 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: G061 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate G061's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: G061 is good value based on its PB Ratio (1.8x) compared to the DE Biotechs industry average (3.5x).
How is Genkyotex forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: G061 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: G061 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: G061 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if G061's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if G061's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if G061's Return on Equity is forecast to be high in 3 years time
How has Genkyotex performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: G061 is currently unprofitable.
Growing Profit Margin: G061 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if G061's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare G061's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: G061 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: G061 has a negative Return on Equity (-101.56%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Genkyotex's financial position?
Financial Position Analysis
Short Term Liabilities: G061's short term assets (€7.1M) exceed its short term liabilities (€4.3M).
Long Term Liabilities: G061's short term assets (€7.1M) exceed its long term liabilities (€1.3M).
Debt to Equity History and Analysis
Debt Level: G061's debt to equity ratio (20%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if G061's debt to equity ratio has reduced over the past 5 years.
Inventory Level: G061 has a low level of unsold assets or inventory.
Debt Coverage by Assets: G061's debt is covered by short term assets (assets are 3.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: G061 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: G061 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -12.6% each year
What is Genkyotex's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate G061's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate G061's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if G061's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if G061's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of G061's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Elias Papatheodorou (50yo)
Mr. Ilias Papatheodorou, also known as Elias, has been the Chief Executive Officer at Genkyotex SA since September 30, 2015 and as its Director since February 28, 2017. Mr. Papatheodorou served as Chief Bu ...
|CEO & Director||4.4yrs||no data||no data|
|Founder & Member of Scientific Advisory Board||0yrs||no data||no data|
|Observer||3yrs||no data||no data|
|Chairman of the Board||3yrs||no data||no data|
|Director||11.6yrs||no data||no data|
|Member of Scientific Advisory Board||0yrs||no data||no data|
|Chairman of Scientific Advisory Board||0yrs||no data||no data|
|Independent Director||3yrs||no data||no data|
|Director||3yrs||no data||no data|
|Member of Scientific Advisory Board||0yrs||no data||no data|
Experienced Board: G061's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genkyotex SA's company bio, employee growth, exchange listings and data sources
- Name: Genkyotex SA
- Ticker: G061
- Exchange: DB
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €34.505m
- Shares outstanding: 11.54m
- Website: https://www.genkyotex.com
Number of Employees
- Genkyotex SA
- Forum 2 Archamps Technopole
- 218, Avenue Marie Curie
- Saint Julien En Genevois
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GKTX||ENXTPA (Euronext Paris)||Yes||Common Shares||FR||EUR||Mar 2017|
|G061||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2017|
|GKTXP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Mar 2017|
Genkyotex S.A., a biopharmaceutical company, develops oral small molecule NOX therapeutics. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company’s lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis, a fibrotic orphan disease, and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its second product candidate, GKT771, is a NOX1 inhibitor, which is undergoing preclinical testing targeting various pathways in angiogenesis, pain processing, and inflammation. The company’s research programs include brain penetrant NOX inhibitors to address CNS disorders and NOX inhibitors in oncology. Genkyotex S.A. has a partnership with Serum Institute of India Ltd for the development of prophylactic vaccines. The company was founded in 2006 and is based in Saint Julien En Genevois, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/18 23:14|
|End of Day Share Price||2020/02/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.